AstraZeneca

January 14, 2013

AstraZeneca, VU collaborate to develop new treatments for major brain disorders

AstraZeneca and Vanderbilt University have signed a research collaboration agreement to identify candidate drugs aimed at treating psychosis and other neuropsychiatric symptoms associated with major brain diseases such as Alzheimer’s disease and schizophrenia.

By Bill Snyder